Digest Network Come funziona
Network
/
Società
JC
Non verificato

JCR Pharmaceuticals Co., Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

30 comunicati stampa

Guarda tutti i comunicati
07/10/2025
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Eventi
Fiere
Industria
JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
01/10/2025
Biotecnologia
Farmaceutica
Salute
Mercato del lavoro
Industria
JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
30/09/2025
Salute
Biotecnologia
Sanità
Scienza
Farmaceutica
Eventi
Fiere
Industria
JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
29/09/2025
Multimedialità
Salute
Scienza
Sanità
Farmaceutica
Industria
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of Japan
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
19/09/2025
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Industria
JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
12/09/2025
JCR Pharmaceuticals Celebrates its 50th Anniversary of Advancing Science and Changing Lives
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
08/09/2025
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Industria
JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
02/09/2025
Multimedialità
Mercato del lavoro
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
28/08/2025
Scienza
Biotecnologia
Farmaceutica
Medicina - Varie
Sanità
Salute
Attrezzature medico-sanitarie
Eventi
Industria
JCR Pharmaceuticals to Present at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) 2025
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
16/07/2025
Biotecnologia
Farmaceutica
Salute
Industria
JCR Pharmaceuticals Selected for Japan’s Regenerative Medicine CDMO Subsidy Program
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0